TCR2 Therapeutics (TCRR) was surging past 48% after it released positive interim data from its phase 1/2 study of TC-210, a drug candidate intended for the treatment of mesothelin-expressing solid tumors.
MediciNova (MNOV) was gaining over 13% in value as it obtained exclusive worldwide rights to develop BC-PIV, a human parainfluenza virus type 2 vector, into a potential vaccine against SARS-CoV-2, the virus that causes COVID-19.
Moderna (MRNA) was up more than 8% after saying it has started dosing the first patients in the phase 3 clinical trial of its mRNA vaccine candidate, mRNA-1273, against COVID-19. Earlier, the company said it will receive an additional commitment of up to $472 million from its contract with the Biomedical Advanced Research Development Authority (BARDA) for the development of its COVID-19 program.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.